|
Dr. Foley is currently Director of the Chemical Biology Platform and Director of Medicinal Chemistry at the Broad Institute, a research collaboration of MIT, Harvard and its affiliated hospitals and the Whitehead Institute. Dr. Foley is one of the scientific founders of CombinatoRx and a leading expert in solid-phase synthesis of stereochemically complex small molecules and medicinal chemistry. Dr. Foley was previously Vice President of Chemical Technologies at Infinity Pharmaceuticals. Dr. Foley was a fellow at the Harvard Institute of Chemistry and Cell Biology (ICCB), a joint academic institute between Harvard Medical School and the Graduate School of Arts and Sciences. Dr. Foley served as the Head of Chemical Technology for the ICCB. Prior to his academic faculty appointment, Dr. Foley worked in the pharmaceutical industry for more than 10 years, building up his base of expertise in medicinal chemistry at Bristol-Myers Squibb and Glaxo Wellcome. Dr. Foley earned his Ph.D. in chemistry at Harvard University in the laboratories of Dr. Stuart Schreiber, researching the interface of chemistry and biology. | 